Jazz Pharmaceuticals Announces First Quarter 2021 Financial Results
Continued Zepzelca Growth Across Second-Line SCLC Setting
Xywav in Idiopathic Hypersomnia Granted FDA Priority Review and an August 12, 2021, PDUFA Target Action Date
On Track to Close Acquisition of GW Pharmaceuticals plc in Early May, Creating an Innovative, High-Growth, Global Biopharma Leader
Secured $5.35 Billion Financing Including $1.5 Billion Senior Secured Notes in Connection with GW Acquisition
23% of Revenue from Recently Launched Products; Total Revenues Increased 14% to $607.6 Million Compared to First Quarter 2020
2021 Total Revenue Guidance Affirmed at $2.55 Billion to $2.70 Billion
DUBLIN, May 4, 2021 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2021 and affirmed financial guidance for 2021.
team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, held April 17–22. Go here to read stories from the conference.
After starting treatment with the multiple sclerosis (MS) therapy Mavenclad (cladribine), some types of immune cells are more affected than others, a new analysis suggests.
The findings may have important implications for understanding how Mavenclad works in MS patients, as well as understanding how vaccines still may be effective in people taking this immune-suppressing therapy.
Mavenclad is an approved treatment for active relapsing forms of MS in the U.S. Originally developed to treat certain cancers, Mavenclad is believed to work by reducing levels of immune cells that drive inflammation in MS. However, it’s not clear exactly how immune cell dynamics are affected by Mavenclad treatment, or how these dynamics are tied to changes in MS symptoms following treatment.
team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
There is a lack of diversity among neurologists, who are disproportionately white men, but new programs aimed at inclusivity may help neurologists to better reflect the communities they serve.
Racial, ethnic, and gender disparities among neurologists, and strategies to address them, were discussed in several talks at this year’s virtual American Academy of Neurology Annual Meeting, which began April 17 and ends today.
Diversity among neurologists and other doctors is important for delivering optimal healthcare. Research has shown that increasing minority representation among healthcare providers can lead to better outcomes for minority patients, through factors like increased cultural competency (the ability to understand and interact with people of a particular cultural background), which is critical for bridging disparities in hea
team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Common B-cell depleting therapies, such as rituximab and Ocrevus (ocrelizumab), may result in shorter duration B-cell depleting effects in African American patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD) than in white patients, a study suggests.
“While previous research has shown that this type of [into-the-vein] therapy is effective for people with those diseases, we also know that Black people tend to have more severe courses of MS,” llya Kister, MD, said in a press release. Kister, of the NYU Grossman School of Medicine in New York, is the study’s senior author and a fellow of the American Academy of Neurology.
Racial disparities present in MS treatment, disability severity Source:
Rivera V, et al. Sociodemographic and Clinical Characteristics of Patients With Multiple Sclerosis by Race and Ethnicity (NARCRMS Registry). Presented at: American Academy of Neurology Annual Meeting; April 17-22, 2021 (virtual meeting). Disclosures: Rivera reports receiving honoraria from Biogen, EMD Serono and Roche. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.